Biocartis Expands Collaboration with LifeArc Kumar Jeetendra | September 1, 2020 Mechelen, Belgium, and London, UK, 1 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the expansion of its collaboration with LifeArc, a UK based independent medical research charity, with a new agreement aimed at the development of highly innovative prototype assays in the …
Sanofi more certain about its coronavirus immunizations Kumar Jeetendra | August 29, 2020 Sanofi’s assurance in its own coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to commence clinical trials, its chief executive told Reuters. The company is working on two of their more than 150 potential vaccines being developed throughout the world to tackle the COVID-19 pandemic, which has maintained over 831,000 lives …
Alembic Pharma gets USFDA’s’ speculative endorsement for type 2 diabetes DRUG Kumar Jeetendra | August 29, 2020 In a regulatory filing, Alembic Pharmaceuticals said it has received tentative approval by the US Food and Drug Administration (USFDA) for both Empagliflozin and Linagliptin pills in the strengths of 10 mg/5 mg and 25 mg/5 mg. Alembic Pharma stated it is now in litigation with Boehringer at District Court of Delaware and launch of …
FDC dispatches 2 variations of Favipiravir in India at Rs 55 for each tablet Kumar Jeetendra | August 25, 2020 Drug firm FDC Ltd on Tuesday said it has established two variants of this COVID-19 drug Favipiravir under the brand names PiFLU and Favenza. The Drug Controller General of India (DCGI) had previously approved the use of Favipiravir, an off patent, oral antiviral drug that’s been demonstrated to quicken clinical healing from COVID-19 patients with …
AstraZeneca begins preliminary of antibody treatment for COVID-19 Kumar Jeetendra | August 25, 2020 AstraZeneca said on Tuesday it began early stage trials to get an antibody-based treatment for the prevention and treatment of COVID-19, as the British drugmaker also ploughs on with its vaccine candidate. The trial will assess if AZD7442, a blend of two monoclonal antibodies, is tolerable and safe in up to 48 healthy participants between …
Moderna finishes up cutting edge chats with EU for COVID-19 immunization gracefully Kumar Jeetendra | August 24, 2020 Moderna Inc said on Monday it’s concluded advanced exploratory talks with the European Commission to supply 80 million doses of its COVID-19 vaccine candidate. The potential arrangement provides for an option for member states to get an additional 80 million doses for a total of around 160 million doses, the business said.
Lincoln Pharmaceuticals Ltd reports 23% rise in the Standalone Net Profit at Rs.14.99 crore in Q1FY21 Kumar Jeetendra | August 20, 2020 August 20, 2020: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 14.99 crore for the Q1FY21 Ended June 2020 as against net profit of Rs. 12.16 crore in the corresponding period last year, growth of 23.2%. Net revenue for the quarter ended June 2020 reported at Rs. 103.01 …
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Kumar Jeetendra | August 20, 2020 India, Mumbai, August 20th , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due …
Oxford-AstraZeneca antibody might be the main shot accessible for Indians Kumar Jeetendra | August 19, 2020 Amid the COVID-19 pandemic, India appears for Oxford-AstraZeneca vaccine candidate are the likely first shot available for Indians at the end of 2020. Additionally, there are two indigenously developed vaccine candidates, that are likewise being anticipated to have started with a gap few weeks if removed in trials, said a report from The Times of …
Dr Reddy’s dispatches Avigan (Favipiravir) tablets in India Kumar Jeetendra | August 19, 2020 Dr Reddy’s Laboratories on August 19 announced the launch of Avigan (Favipiravir) pills, used for treating mild to moderate COVID-19 sufferers in India. Dr Reddy’s stated Avigan was approved by the Drugs Controller General of India (DCGI) for treating patients with moderate to medium COVID-19. “The need for high efficacy and quality, affordability and improved …
Vaccine firm Biological E gains Akorn’s injectable plant in India for $10 million Kumar Jeetendra | August 17, 2020 Vaccine maker Biological E (BE), on August 17 stated it has acquired Akorn India, a subsidiary of US-based Akorn which generates speciality generic injectable medicines and vaccines for around $10 million in money. BE said the acquisition will allow the Hyderabad-based organization to boost its manufacturing capabilities and abilities to produce and furnish its vaccines …
In procedure of acquiring natural freedom for new plant in Madhya Pradesh: Ipca Labs Kumar Jeetendra | August 16, 2020 New Delhi, Aug 16 (PTI) Medicine manufacturer Ipca Laboratories is in the process of getting environmental clearance for a new production plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report. Sharing information with the firm”s shareholders, the drug maker said the company has already acquired land to the job. “The organization is in …
